CP2 and SP1 cells were derived from genetically modified mouse prostate cancer models that represent activation of β-catenin and inactivation of Sprouty2 along with the loss of Pten tumour-suppressor protein, respectively.10 (link),11 (link) Details of the CP2 (RRID:CVCL_VQ85) and SP1 (RRID:CVCL_VQ86) cell lines have been deposited on the RRID Portal (https://scicrunch.org/resources/). Cells were grown in DMEM supplemented with 10% foetal bovine serum (FBS) and 2 mM l-glutamine. LNCaP and PC3 cells were obtained from American Type Culture Collection and were grown in RPMI supplemented with 10% FBS and 2 mM l-glutamine. RPE1 cell lines stably expressing H2B-RFP, GFP-tubulin or EB3-GFP were maintained in the DMEM/F-12 medium supplemented with 10% FCS, 2.3 g/l sodium bicarbonate, 100 U/ml penicillin, 100 μg/ml streptomycin and 500 µg/ml geneticin. Cell lines were authenticated by LCG standards or in-house using Promega GenePrint 10 Kit. All cell lines used were routinely tested every 6 months for mycoplasma using an in-house MycoAlert™ Mycoplasma Detection Kit (Lonza, Switzerland), according to the manufacturer’s instructions. RPE1 cells were tested monthly for mycoplasma using a MycoSensor PCR Assay Kit (Agilent Technologies, USA).
Free full text: Click here